is glp semaglutide Another Weight-Loss Trial Win for Weekly GLP-1 Drug GLP-1s | AgelessRx

In the Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide reported an average body-weight reduction of about 24% at 48 weeks

At the time, the effort felt like compliance theater, not expected to change much behavior among GLP-1 compounders or marketers

This guide breaks down everything you need to know, including eligibility criteria, prior authorization, reasons for denial, and cost-saving options

The study found a drop in mean body weight of 14.9% at 68 weeks

In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session